Trilipix Use In Diabetics Might Be Restricted After FDA Panel Review Of ACCORD Data

The agency's Endocrinologic and Metabolic Drugs Advisory Committee will meet on May 19 to consider how cardiovascular outcomes data on fenofibrate use in combination with simvastatin relate to the efficacy and safety of Trilipix, Abbott's second-generation fenofibrate product.